Clinical Trial Update: A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pamiparib with radiation and/or temozolomide for newly diagnosed or recurrent glioblastoma; status completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Pamiparib (pamiparib)

Snippet

Sponsor: BeiGene USA, Inc. | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-31